2026 could redefine obesity treatment, as pills,

Short, food-based fasting activates body’s cle

Despite new White House deals and public pressur

The New England Journal of Medicine has published

Insilico Medicine, a clinical-stage biotechnology

Life Time said it will open its fifth athletic co

Mesoblast Limited announced changes to its Board

Hopeful mouse data suggest restoring the brain’s energy balance could do what decades of research have not: push Alzheimer’s into retreat. For more than a century, treatments for Alzheimer’s disease have largely focused on slowing decline, not turning it around. But a new study from University Hospitals Cleveland Medical Center is quietly challenging that assumption, offering a different way of thinking about the disease. Now, it’s seen not just as toxic buildup in the brain, but as a crisis of energy. In experiments involving mice and human brain tissue, researchers found that restoring balance to a molecule essential for cellular energy dramatically reversed Alzheimer’s-like damage [1]. The findings, published last week in Cell Reports Medicine, do not claim a cure. But they do reopen a door many thought was permanently closed. The center of the study is NAD+, a molecule found in every cell of the body. It helps cells turn nutrients into usable energy and repair everyday damage. NAD+ is especially important in organs that work nonstop, including the brain. Researchers examined two mouse models of Alzheimer’s alongside human Alzheimer’s brain tissue and found the same pattern: severe depletion of NAD+ [1]. “NAD+ naturally declines with age. When NAD+…

Global longevity therapeutics market projected t

As resolutions drive demand, regulators warn aga

New waist-focused criteria suggest more than 75%

Nephrodite’s device designed to ‘free patien

China’s speed, scale and infrastructure are ce

Mount Sinai digital twin study layers wearables,

GLP-1 drugs help with weight and heart health, b

Singapore-based company upgrades its flagship su

Insilico Medicine IPO signals that AI‑native d

Data-rich heart scans are fused with AI to spot

Consumer review highlights growing demand for si

Innovation meets economic caution as life scienc

Autophagy-enhancing drug candidate enters Phase

Epigenetic rejuvenation gears up for the clinic,

Singapore-based healthcare firm expands into ste

As skincare heads into 2026, experts say skin lo

New research suggests that DNA inherited from pr

Using real-time brainwave data, clinics claim to

Healthspan as a universal right, the need for ne

European Commission wants to speed up biotech, f

A collaborative study reports a multi-target nan

Northwestern researchers unveil the most detaile

TruDiagnostic has been recognised in Better Busin

ProHealth Longevity has spotlighted its oral BPC-

LiveForeverHealth announced the launch of a full-

Study links statin use to slower cognitive decli

Longevity-linked enzyme shown to regulate brain

Long-term data suggest newly approved therapy ca

The approval marks a milestone for GLP-1 drugs,

From models and measurement to clinics and compe

Partnership targets cold-chain bottlenecks by co

By targeting a hidden toxic protein, an experime

CPN expands beauty and wellness push, partnering

Fastenal Company said Daniel L.

Boosting mitochondrial supercomplex assembly imp

US President says agreements with more drugmaker

Liom boasts miniaturization breakthrough in spec

Anavex is pushing for a second look at a potenti

A pilot clinical trial led by researchers at Ceda

Humacyte announced the publication of long-term c

Biosplice Therapeutics said the first patient has

An end-of-year experiment exploring how large la